Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958831 | 0.92 | KCNH2 (0.40) | KCNH2KDM5BHRH4 | |
| SCHEMBL1960353 | 0.84 | KDM4E (0.38) | KCNH2KDM5BCYP19A1 | |
| SCHEMBL1963287 | 0.82 | RAB9A (0.42) | KCNH2KDM5BCYP19A1 | |
| SCHEMBL1961657 | 0.81 | KCNH2 (0.41) | KCNH2KDM5BCYP19A1HRH4 | |
| SCHEMBL1958046 | 0.78 | KCNH2 (0.41) | KCNH2KDM5B | |
| SCHEMBL1960665 | 0.77 | SMN1; SMN2 (0.44) | KCNH2 | |
| SCHEMBL1961659 | 0.73 | LTA4H (0.36) | KCNH2KDM5BHRH4 | |
| SCHEMBL1961171 | 0.73 | KDM4E (0.37) | KCNH2KDM5BCYP19A1 | |
| SCHEMBL13137747 | 0.72 | KDM5B (0.42) | KDM5BHRH4 | |
| SCHEMBL16628721 | 0.71 | KCNH2 (0.42) | KCNH2KDM5BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332938-B1 | Viral inhibitors | LEUVEN K U RES & DEV (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | KCNH2 2470/4885KDM5B 590/4885CYP19A1 3722/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | KCNH2 2142/4885KDM5B 963/4885CYP19A1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.